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There has been a large increase in the number of prescriptions for opioid drugs in the UK 
over the last twenty years or more and the prescribing of opioids in high doses continues to 
increase.  Much opioid prescribing is for chronic non-cancer pain (CNCP) despite serious 
doubts about the long-term effectiveness of opioids for this indication.  Clinical experience 
is that there are increasing numbers of patients who are on high dosages of opioid drugs 
over sustained periods which provide limited or no pain relief whilst having significant 
negative effects on functioning and quality of life.   The aim of this paper is to bring readers’ 
attention to some clinical observations of the CNCP population with high doses and to 
describe an intervention to reduce these doses.  Many of these patients have no clinical 
features of addiction; we suggest that those who show little or no substance misuse 
behaviours are best understood as a distinct clinical population who have different 
treatment needs.  In order to understand and treat these patients, a model is required 
which, rather than seeing the problem as lying solely with the patient, focuses on the 
interaction between the individual and his or her environment and seeks a change in what 
the patient does every day, rather than a simple, and  largely unattainable, goal of symptom 
elimination.  The clinician authors worked together to develop an intervention based upon 
approaches taken from both pain management and psychiatric practice.  A detailed 
description of this rapid opioid reduction intervention (RORI) is provided along with some 
preliminary outcome data. 
Keywords: opioids; methadone; chronic pain; pain management; drug reduction; psychosocial 
intervention 
  





Background and Rationale 
There has been a large increase in the number of prescriptions for opioid drugs in the UK 
over the last twenty years or more [1-5].  Recent research suggests that this pattern has not 
reversed [6,7]. There is evidence of continuing increases in the use of strong opioids and 
high doses [8,9].  There have been similar increases throughout the developed world [10], 
with the largest increases in North America [11-13].  Most of this prescribing is for chronic 
non-cancer pain (CNCP) [2,4,8] despite serious doubts about the long-term effectiveness of 
opioids for this indication [14-18].  There is evidence of direct and indirect harms resulting 
from such use of opioids [15,19-24].  
There are problems with other drugs used in the treatment of CNCP, but the lethal potential 
of opioids causes particular concern.  In the UK, there has been a focus on avoiding the 
severe problems encountered in the USA [25-28]. 
Distinct population 
Concomitant to the increase in prescriptions, a significant minority of chronic pain patients 
across the NHS take high doses of opioids for long periods.  For many patients, these high 
doses provide little or no additional pain relief over more modest dose regimens, whilst 
producing significant negative effects on functioning and quality of life [29].  We have 
labelled this phenomenon Dysfunctional Therapeutic Opioid Use (DTOU). 
There is a temptation to see all of the problems encountered by long-term users of opioids 
for CNCP in terms of substance misuse and to suggest that they can be dealt with through 
substance misuse treatment approaches.  There are similarities between substance misuse 
and DTOU patients in the effects of the drugs they use and some DTOU patients show some 
clinical features of addiction, such as lying to family about their drug use or hoarding 
medications.  However, many DTOU patients have no clinical features of substance misuse.  
Where clinical features of addiction predominate, referral to substance misuse services is 
appropriate.  We suggest that those who show no (or only minor) substance misuse 
behaviours are best understood as a distinct clinical population who have different 
treatment needs.  
This is not to deny that some people with a primary addiction problem obtain drugs through 
pain prescriptions or that opioid use for CNCP sometimes leads on to addiction.  Instead, we 
suggest that the conceptualisation of the problems of DTOU patients as necessarily a form 
of substance misuse is misleading and unhelpful.  A substance misuse model assumes 
motivations for use other than chronic pain, and consequently cannot be used to address 
the specific problems of DTOU patients.  Treatments for substance misuse and for chronic 
pain have different objectives.  For substance misuse they are drug substitution, harm 
reduction and, ultimately, abstinence; for chronic pain they are optimising pain relief and 
personal functioning, balancing drug benefits and adverse effects.  What they have in 
common is a need for harm reduction. 
In North America, considerable research attention has been paid to substance misusers and   
pain management services (see, for example, [30-38]).  This has two main aims.  The first of 
these is to identify patients who have an established substance use disorder, in order to 





prevent abuse of the services.  The second is to identify factors predicting the development 
of substance misuse amongst those who are prescribed opioid medication.  Whilst the 
approach is logical, it has not proven fruitful; systematic reviews suggest that it has not led 
to the development of reliable instruments with adequate specificity and sensitivity [15,39, 
40 and see 41,42].   
We agree with the formulation of Schofferman [43] who describes an upward spiral of 
opioid use whilst the patient’s functioning spirals downward.  He says 
…patients may become less functional.  They may become depressed, anxious, or irritable.  
They often have disturbed sleep.  Patients usually attribute the problems to the continued 
pain, not to the opioids.  Their life may become more centered around appointments with 
doctors, often to renew medications.  These patients are not malingering, exaggerating, or 
abusing their drugs.  They are seeking pain relief. [p 286; emphasis added]. 
Clinical observations  
On first assessment, many patients referred to UK secondary care pain management services have 
often been prescribed high doses of opioid medication for some time: and yet the usual reason for 
referral is inadequate pain relief.  Most are also prescribed adjuvant medications, many of which are 
sedative, have dependency-forming potential, and exacerbate opioid adverse effects. 
In primary care, indirect (aggregated prescribing data) and anecdotal evidence suggest that 
a significant number of patients who are not known to pain management services are 
prescribed high doses of opioids for CNCP. There are few studies of these patients.  It is 
reasonable to suppose that a proportion of them have, or will develop, DTOU.  
It is not clear how high-dose and high potency regimens originate.    Whilst for some 
patients, high doses appear to develop in primary care, other patients are discharged from 
hospital on high potency opioids without clear plans for using or stopping these 
medications.  In addition, some pain management clinicians advocate high-dose and high 
potency regimens. 
There are some common features evident from treating such patients in secondary care 
pain services.  
Resistance to dose reduction 
Patients often experience some pain relief at the beginning of treatment with opioids, but 
this does not persist.  This means that the goal of successful pain relief through medication 
can appear attainable to them. 
These patients go through an escalating cycle of pain and drug doses where initial pain 
reduction is followed by a return to previous pain levels, addressed by increased doses.  This 
is successful in the short term but is followed by returning pain, and so on.  This attenuation 
of pain relief is often interpreted by many patients and their doctors as evidence of 
worsening of their painful condition.  However, in a proportion of cases, it is likely to be due 
to opioid-induced hyperalgesia (that is, pain that diminishes in intensity when opioid 
medication is reduced or discontinued), a recognised effect of continuous use of opioids, 
particularly in high doses [20,21,44].  Some analyses of the mechanisms for hyperalgesia 





suggest that it is closely linked to tolerance [45,46] and that, like tolerance,  it may be a 
universal property of opioids [46].    
In our experience, people who have endured severe chronic pain are fearful of its return. 
Warnings about the dangers of high doses of opioids often confirm their belief that their 
pain is exceptionally severe and deteriorating, and that they will be overwhelmed by pain if 
the drugs are reduced or discontinued.  
Lack of evidence on reduction of high doses of opioid 
There is a lack of reliable research evidence for the prescription and use of opioid 
medication for CNCP [15,17,47,48]; a recent Cochrane review failed to find high quality 
evidence on the use of high doses of opioids for CNCP [18].  There is also a paucity of 
evidence-based interventions for the reduction of high doses of opioids [49,50]; expert 
guidelines recommend the staged reduction or tapering of prescribed opioid doses where 
necessary [51-55] but there appear to be few studies evaluating the effectiveness of this 
procedure in pain patients.  Two recent reports of trials of tapering with patients with 
prolonged high doses of prescribed opioids raise questions about the likely effectiveness of 
this procedure with this patient group [56,57].  Both studies encountered serious difficulties 
with the recruitment and retention of participants and in achieving compliance with the 
study procedures. This resulted in a failure to complete the planned interventions.  Other 
researchers have questioned the effectiveness of tapering with users of high-dose opioids 
and suggested that, in some patients, it results in deteriorating health [58].  Our clinical 
experience is that patients find slow tapering difficult due to the repeated initial increase in 
pain following dose reductions and the lack of immediate and marked benefits. 
Model of care in pain management 
Substance misuse services and pain specialists both treat some patients with chronic pain 
and drug related problems and both groups use models which primarily locate problems in 
the patient.  Pain physicians routinely look for physiological sources of pain which can be 
addressed through physical intervention or through drugs.  Difficulties, and conflicts with 
patients, arise when physiological sources cannot be identified or effective interventions 
cannot be devised.  Substance misuse models also focus on patient vulnerabilities 
(physiological, genetic, psychological or social) which lead to addiction problems on 
exposure to substances.   
We suggest that, in order to understand and treat DTOU, a model is required which, rather 
than seeing the problem as lying solely with the patient, sees it as a trap into which patients 
and prescribers can fall, in which the prescriber, the health system and patient factors all 
play an active role.  A model is needed which focuses on the interaction between the 
individual and his or her environment and seeks a change in what the patient does every 
day, rather than a simple, and  largely unattainable, goal of symptom elimination. 






Process of an intervention development 
An experienced liaison psychiatrist (RP) with an interest in substance misuse offered one 
session/week with a hospital based pain management team, mainly assessing inpatients on 
high-dose opioids.  In some cases, methadone substitution was commenced during the 
admission.  Following national prescribing guidelines [59], the starting dose was methadone 
20mg/day.  Few patients needed an increase in methadone dose to control pain or 
withdrawal symptoms, and the patients did not report drug craving.  Some patients needed 
follow up, and a specialist clinic was set up. Over time, working within the pain management 
team, outpatients were referred for intervention.  The regimen set out below was 
developed for these outpatients by the same psychiatrist and an experienced clinical nurse 
specialist in pain management with the aim of reducing from high doses of standard opioids 
to low dose methadone, which is distinct from methadone substitution in harm reduction 
management of opiate addiction.  Intervention development relied upon first principles of 
rational prescribing [60] and trial-and-error to find strategies that might help to reduce 
medication adverse effects and improve patients’ quality of life without a worsening of pain. 
Low dose methadone was just one treatment option that was offered to appropriate 
patients. 
The intervention that has been developed relies upon four conceptual elements: 
1. The patient.  A clear understanding of each patient’s circumstances and experiences 
of pain and medication, along with an exploration of their meanings and the 
expectations which patients have for treatment.  The involvement of family 
members or carers is important; they help in understanding the patient’s 
circumstances and are often influential in changing or maintaining the patient’s 
medication use. 
2. The prescriber.  In every case, a prescriber initiates these regimens and has increased 
dosage in good faith, despite a lack of persistent pain relief, impairment of social 
functioning and poor quality of life.  Understanding the prescriber’s dilemma, and 
providing them with responses other than drug treatment is essential if change is to 
be sustained. 
3. The drugs.  A sophisticated understanding of both pain and the drugs used to treat it 
are crucial. In some areas there is a serious lack of evidence, particularly with regard 
to hyperalgesia and effects on mood and cognitive functioning.  
4. Health care systems.  It is necessary to pay attention to the new ways that an over-
stretched healthcare system functions, often with unintended consequences such as 
atomisation of care and the loss of clear locus of control of treatment.  
Administrative actions, such as formulary changes designed to reduce prescribing of 
drugs of particular concern (e.g. tramadol), can focus prescriber attention on ‘which 
drug?’ rather than encouraging a broader framework of  pain management.  It is also 
necessary to consider wider social factors, including the impact of the attitudes, 
expectations and assumptions of patients and prescribers about pain and about 
healthcare and its delivery.  





The developed intervention 
The rapid opioid reduction intervention (RORI) is offered to patients who have been 
assessed by the secondary care pain management service.  The purpose is to optimise 
medication use and promote non-pharmacological pain management strategies.  Patients 
are accepted who are on long-term (12 months or more) high dose opioid medication 
regimens (using the generally accepted criterion of ≥120mg/day oral morphine equivalent 
{ME} dose [29]) with poor pain relief and where the pain management multidisciplinary 
team consider medication reduction is necessary. This may arise before or after other pain 
interventions, or where other treatment options have been exhausted.  
RORI depends upon joint working by a pain nurse specialist and a consultant psychiatrist 
who are able to deliver a fundamentally psychosocial intervention, whilst attending to 
biomedical aspects of the patients problem.  We understand our patients and their doctors as 
being caught in a trap which can only be escaped by a complete change of strategy by all concerned.  
Accordingly, the intervention draws the principles of Milan School systemic family therapy 
(direct involvement of family members, neutrality, circularity, hypothesising, positive connotation, 
paradoxical intention) [61,62] as well as more commonplace elements of pain management 
such as careful history taking, attention to the origins, development and effects of their 
painful condition(s), and the use and consequences of all drugs taken to alleviate pain.  
Table 1 sets out the main psycho-social elements of the intervention.  At the time of writing, 
the intervention is not manualised. 
 
Table 1 about here 
 
There is a careful explanation of the rationale for radically reducing opioids and adjunctive 
medications (benzodiazepines, other hypnotics and anxiolytics, antidepressants, GABA 
drugs).  When necessary, before the opioid intervention, there is rationalisation or 
reduction of adjuvant medication, using standard dose tapering strategies, taking into 
account the drug, the dose and the patient’s needs.   
In RORI, the outcome offered is that pain will be no worse but that the patient’s overall 
condition will improve.  Patients are offered informed choices between no change, graded 
reduction or rapid reduction of their opioid drug regimens.  We recommend the latter 
strategy, as it appears to be the most effective, particularly where high dose opioids are 
replaced by very much lower doses of methadone (typically methadone tablets 10mg twice 
a day).  In all approaches, the prescription of additional (‘PRN’) doses for when pain is 
particularly severe is strongly discouraged and with methadone it is forbidden.  In our  
preferred regimen, the changeover is conducted on an outpatient basis over Sunday-
Monday night.  Loperamide is used to control gastrointestinal withdrawal symptoms.  There 
is a pre-arranged telephone contact after 36 hours and a face-to-face joint review on day 4. 
This is repeated the following week.  Patients, relatives and their GP are given a number to 
contact within working hours for advice.  GPs and patients are advised that until discharge 
from follow up, all decisions regarding pain medication should be made by the specialist 





team.  This warning is placed on primary care records, along with the information that the 
patient is receiving methadone for treatment of pain rather than addiction.  The patient is 
given a card to carry with this information and contact numbers.  Recognising that specialist 
support is only available within office hours, all warnings and doctor/patient information 
also carry the advice that, in the event of an intervening medical emergency requiring 
strong analgesia, methadone should be discontinued and the patient should be managed as 
if opioid naïve (that is, ignoring any earlier opioid tolerance).   
Patients are offered follow-up support for as long as they wish post-intervention, with the 
option of returning to their previous approach (but not previous doses) if they wish.  Further 
non-drug interventions, focusing on learning to manage rather than eliminate pain, are 
offered (see Table 2).  Supplementary documents are provided for procedural description of 
the intervention including information leaflet for GPs (Sup 1), and RORI procedure (Sup 2).  
The intended patient outcomes of RORI are: improved day-to-day functioning; improved 
mood; improved cognitive functioning; improved patient safety (for example through 
reduction of risk of accidental overdose); improved sense of personal agency; improved 
ability to engage with non-pharmacological pain management.  These outcomes are often 
not satisfactorily captured through standardised outcome measures.  We will separately 
report a qualatitive study examining patients experience before and after opioid dose 
reduction.  Outcome measures that we have trialed include: Brief Pain Inventory [63] pain 
location and current pain level measures; Hospital Anxiety and Depression Scale [64]; a 
specially constructed measure of Participation in Social Roles and Activities using validated 
items from PROMIS [65]; and pulse oximetry.  So far, insufficient data has been collected to 
provide satisfactory measures of outcome, but this is work in progress. 
The intervention is associated with a substantial programme of related research about 
various aspects of patient experience, the effects of high dose opioids on individual patients 
and prescribing patterns in primary care. Findings from this programme of research will be 
submitted for publication shortly.  
Table 2 about here 
Evaluation1 
During 2014, patients were seen from time-to-time in an existing nursed-led pain 
management clinic. In 2015 a separate formal monthly joint clinic (LJ and RP)  was set up 
and in July 2017 this became a weekly clinic. A small number of patients were seen where 
the primary medication of concern was not an opioid or opioid doses were below the level 
at which RORI would usually be offered. All patients had previously been fully assessed by 
the pain management team. Data was routinely collected to monitor and evaluate the clinic.  
 
1 For the reporting of routinely collected data, permission was obtained from the local Clinical Audit and 
Effectiveness Department and ethical approval was given by Bangor University School of Health Sciences Ethics 
Committee.  For the qualitative study data reported, the research was approved by the Research Ethics 
Service, Wales Research Ethics Committee 5 (18/WA/0065) and by Bangor University School of Health Sciences 
Ethics Committee (2018-16258); all participants gave informed consent at the start of this study. 





Between 2014 and February 2020, 87 patients were assessed in the clinic. 41 (47%) of the 
patients were female;  the median age at referral was 51, range 25-77, IQR 43-58. 
28/87 (32%) did not engage, in that they either failed to attend their first or second 
appointment and did not accept invitations to be seen again.  The proportion of referred 
patients who do not engage decreased over time. 
20/87 patients (23%) chose rapid change to low dose methadone.   Their mean daily opioid 
dose at referral was 357mgME2, range 80-800mgME.  Four (20%) methadone patients switched 
back to other opioids.  One patient requested this because of inadequate pain relief and in 
another case methadone was stopped on safety grounds after a  concurrent opioid was 
commenced by a different team. Neither of these patients returned to their previous level 
of ME doses in the next 12 months. Two other patients had methadone discontinued for 
medical reasons. There were no critical incidents amongst any of the 20 methadone 
patients, and none has died.  
20/87 are currently active clinic patients and have not undergone the rapid dose-reduction 
intervention.  Their mean daily opioid dose at referral was 233mgME, range 38-720mgME.  
A number of these patients have been assessed as unsuitable for methadone (for example, 
because of medical contraindications, chaotic life circumstances or history of taking opioids 
above prescribed doses) or have doses below the usual intervention threshold; some have 
undergone alternative medication rationalisation interventions.  Eleven patients remain as 
future candidates for the intervention.   
The remaining 19 patients either accepted more gradual reduction; or decided against dose 
reduction of opioids; or reduced other drugs.  They were discharged by agreement with the 
patient to GP care once active intervention and regimen changes were complete. A few 
patients were discharged back to the care of the main pain management team where a 
specific intervention was indicated. 
As part of a separate, ongoing qualitative study of patients’ and family members’ 
experiences of chronic pain and the use of long-term high-dose opioids, interviews were 
conducted with ten  patients after the change to low-dose methadone.  Nine out of ten 
reported that prior to the change, increasing doses of opioids had not eased their pain.  
Nine out of ten reported an improved or  much improved mood after the change.  All 
reported increased alertness.  Seven out of ten reported improvement in pain; two reported 
no change in pain; one reported some deterioration in pain (but the latter patient reports 
positive outcomes overall.)  Six out of ten reported increased levels of activity;  several of 
these patients have activity-restricting underlying medical conditions.  These self-reports 
were confirmed in the seven cases where partners were interviewed.  All of the patients and 
their partners emphatically rejected the idea of a return to their previous drug regime. 
 
2 Morphine equivalent doses were calculated using ratios published by the Royal College of Anaesthetists 
Faculty of Pain Medicine [66] 






In summary, there is currently much concern about over-prescription of the opioid 
medication for CNCP, particularly the higher potency drugs and higher doses.  Nevertheless, 
there is little evidence on how people on long-term high dose medication regimens can be 
helped to optimal pain management.  We suggest that this requires a broader 
understanding of pain and its treatment.  We also suggest that the problem is not mainly 
due to bad prescribers or drug-misusing patients.  However, prescribers must recognise the 
potential adverse consequences of a commonly utilised treatment.  It is incumbent upon 
individual clinicians and managers of health services to take responsibility for limiting them.  
We have developed an intervention that appears to help a proportion of patients on high-
dose long-term opioids whose problems previously appeared intractable. However, whilst 
the audit data presented here is promising, our data must be interpreted with great caution. 
No firm claims of effectiveness can be made without a proper clinical trial.  
Conclusion 
This paper describes an intervention for DTOU and sets out the conceptual framework that 
was helpful in developing it.  Although our experience suggests that the approach is 
effective and safe, including treatment with low dose methadone, we cannot yet provide 
high quality evidence to support this assertion.  We offer it here as a contribution to the 
conceptual development of new responses to intractable pain and ‘the opioid crisis’.  Our 
clinic is the focus of research activity, and we will be reporting findings from a longitudinal 
community prevalence study and a qualitative study of patient and carer experience in the 
near future.  The clinic is audited and we are seeking funding to more comprehensively 
evaluate the intervention.  
  





Table 1: Main psychosocial elements of the intervention  
• Engagement & rapport. 
o Involvement of family or partner wherever possible. 
o Preparedness to listen; history-taking focuses on the story that the patient 
and family want to tell. Where applicable, to accept the sense of grievance or 
betrayal by specific practitioners or the health system in general; to 
acknowledge feelings of powerlessness, hopelessness and abandonment. 
o Acknowledgement of the validity of their perspective. 
o Avoidance of explicit or implicit patient blaming (e.g. avoiding medication 
“contracts”) or doctor blaming (positive connotation of motivations for past 
decisions). 
o Acknowledgement of pain and of compliance with past medical advice.  
o Exploration of health beliefs. Acknowledgement of limitations to medical 
tests and understanding. 
 
• Agreement of new treatment aims. 
o Explanation of chronic pain and its relationship to tissue damage. 
o Provision of verbal, written and digital information. 
o Setting of limited goals (i.e. to feel better with pain no worse). 
o Prediction of fluctuations in pain irrespective of medication regimen. 
 
• Rationalisation of medication and radical reduction of opioids. 
o All medication changes made with patient agreement (as consent is not 
essential for medication discontinuation). 
o Permanent option for patiernt to  return to previous drug regimen. 
o Mandatory cooling-off period or thinking time for decision to start dose 
reduction. 
o Frank acknowledgement that rapid transition to low-dose opioids will involve 
unpleasant (but not dangerous) short-lived withdrawal effects. 
o Provision of intensive support during transition. 
 
• Post medication change work. 
o Reassurance that follow up will continue until regimen is stable, and that 
discharge will only occur by prior agreement. 
o Exploit functional improvement through problem-solving approach to 
achieve self-determined targets. 
o Overcome demoralisation, low expectations and restricted life objectives and 
restore hope. 
o Complete discontinuation of analgesia (and adjuvant medications) where 
patient wants this by tapering residual medication. 










Table 2: Non-pharmacological pain strategies 
• Time and timing: offer patients non-pharmacological interventions when they are 
ready, rather than at the outset when they are still focused on a pharmacological 
solutions. 
• Set expexctations and specific treatment goals for each intervention. 
• Provision of information e.g. on posture, firm upholstery, and low back pain and 
sofas. This often has to be repeated several times. 
• Advice on distraction, relaxation and use of heat packs or TENS machines. 
• Acupuncture. 
• Physiotherapy assessment and intervention. 
• Clinical psychology intervention where there is a clear goal for this. 
• Concurrent involvement in a short Educational Patient Programme or a 
comprehensive Pain Management Programme. 
• Where waiting times are excessive or patient preference is for one-to-one work, Pain 
Management Programme can be delivered through a workbook. 
• Recommendation to use voluntary sector resources such as chronic pain support 
group or counselling services.  
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Complex Medication Clinic:  
 




The medical management of long term painful conditions is complex, and this clinic exists in order to 
maximise patient’s quality of life. For many patients with chronic non-cancer pain, the outcome of 
treatment is disappointing. They often have poor symptom relief despite high doses of opio id and 
adjunctive medications, and there is a high burden of side-effects.  
This poor outcome is in part due to opioid-induced hyperalgesia, which can trap patient and 
prescriber alike in a cycle of increasing doses, with initial improvement in symptoms that is not 
sustained over time. 
Although some patients on high doses of opioids and GABA drugs have characteristics suggestive of 
addiction, this clinic does not primarily cater for that group. We do, however, sometimes make 
referrals to Substance Misuse Services where this is appropriate. 
The rationale underlying our programme is that withdrawal of unhelpful medications and reductions 
in dosage can lead to better pain management through reduced cognitive and mood side effects, 
alongside teaching patients to manage their pain. This is a more realistic approach than perpetuating 
an unattainable target of pain elimination through medication. 
The clinic is part of the Pain Management Team service, and is conducted by Lucy Jones, senior 
nurse specialist in pain management, and Rob Poole, Professor of Social Psychiatry and Honorary 
Consultant Psychiatrist.  
In the clinic, we reassess people’s pain and personal histories. In the case of adjunctive medications, 
withdrawal and/or discontinuation is achieved through a supervised graded reduction. In the case of 
opioids, we sometimes conducted graded reduction. However, this is problematic, as hyperalgesia 
means that pain increases on dose reduction before attenuating to the previous level. Graded 
reduction can be a slow and demoralising process before gains are finally seen. It can also feed into 
patients’ fears that their condition is especially severe, requiring massive doses of medication, 
without which they will overwhelmed by pain. 
Consequently, and for selected patients, we offer rapid dose reduction from high dose opioids (in 
excess of oral morphine equivalent dose 120mg per day) to a low dose, f ixed regime of methadone 
10mg bd (adjusted to an absolute maximum of 20mg bd). Methadone is selected because of its 





pharmacokinetic and other properties, not because we believe the patient to be a ‘drug addict’. The 
patient is given a card or letter indicating this. 
This change is effected overnight, with a very high level of preparation and support from the clinic 
for the patient and their family. We do not carry out this process unless the patient fully consents. 
We offer the treatment objective of pain that is no worse than on the previous regime, but with 
significantly less side effects. Most patients experience improved pain relief.  
If patients wish to return to their previous regime (e.g. Fentanyl), we will organise this, albeit at a 
dose appropriate to their current level of opioid tolerance. In our experience, even those patients 
who do this only ever return to a lower dose of opioids than at the start.  
We do not institute this regime if the patient’s GP raises a medical contra-indication. If you feel that 
there is such a contra-indication, please contact the pain team secretary 
(XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX; 01978 725564) 
Management of patients during and after change of opioid regime 
The change is only made when the patient’s family is available  to support them, and when [senior 
nurse specialist] and [consultant psychiatrist] are available to offer telephone/face to face support to 
all concerned, including the GP. 
Methadone is prescribed by [consultant psychiatrist] from the hospital pharmacy. It is essential 
that no other opioids are prescribed for the duration of methadone treatment and that control of 
long term pain medication is retained by the clinic. In the event of an unexpected medical 
complication or trauma that requires opioid analgesia, methadone should immediately be 
discontinued and the patient treated as if opioid niave. [Consultant psychiatrist] or [senior nurse 
specialist] must be informed on [telephone and email] in order to discontinue supply of 
methadone. They will give advice if this is required. 
Patients are instructed to discontinue their standard opioid medication after their last dose on a 
specific Sunday. In the case of patches, the patch is usually removed on the Saturday night. On 
Monday morning, they commence on Methadone 10mg bd, and there is a telephone review by 
[senior nurse specialist] on Tuesday. On Thursday, patient and family are seen in clinic, and continue 
with twice weekly contact until symptoms have stabilised. Patients normally feel substantially 
improved within 4-5 days. About half of patients experience significant withdrawal symptoms, which 
can be controlled to some extent with PRN loperamide whilst diarrhoea and cramps continue. There 
is transient restlessness and sleep disturbance in many cases, and pain may worsen before 
improving again.  
Patients are followed up for as long as is necessary and will not be discharged to GP unless an 
agreement is made with an individual GP for continuing treatment and monitoring.  
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